Pacific Biosciences
PACB
141 hedge funds and large institutions have $432M invested in Pacific Biosciences in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 27 reducing their positions, and 15 closing their positions.
159% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 27
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
9% more funds holding
Funds holding: 129 → 141 (+12)
11% less capital invested
Capital invested by funds: $487M → $432M (-$54.8M)
28% less call options, than puts
Call options by funds: $4.08M | Put options by funds: $5.66M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$22.9M |
| 2 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$15.9M |
| 3 |
BM
Bridger Management
New York
|
+$9.91M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$8.15M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$8.04M |
Top Sellers
PACB Hedge Fund Activity: Q2 2016 in Review
141 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2016, worth a combined $432M — down 11% from $487M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PACB positions and 15 closed out — a net gain of 14 holders — while 70 added to existing stakes and 27 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $22.9M. The largest seller was Consonance Capital Management, cutting an estimated $31.1M.
- 141 institutional investors held Pacific Biosciences (PACB) as of Q2 2016, up from 129 in Q1 2016.
- Funds reported $432M of Pacific Biosciences stock for Q2 2016, down 11% quarter-over-quarter.
- 29 funds opened new Pacific Biosciences positions in Q2 2016 and 15 closed out, a net change of +14 holders.
- The largest Pacific Biosciences buyer in Q2 2016 was Lord, Abbett & Co, an estimated $22.9M added.
- The largest Pacific Biosciences seller in Q2 2016 was Consonance Capital Management, an estimated $31.1M sold.
Based on aggregated 13F filings for Q2 2016.